dc.creator | Livanou E., Rouka E., Sinis S., Dimeas I., Pantazopoulos I., Papagiannis D., Malli F., Kotsiou O., Gourgoulianis K.I. | en |
dc.date.accessioned | 2023-01-31T08:55:20Z | |
dc.date.available | 2023-01-31T08:55:20Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.3390/jpm12040640 | |
dc.identifier.issn | 20754426 | |
dc.identifier.uri | http://hdl.handle.net/11615/75975 | |
dc.description.abstract | Background: SARS-CoV-2 vaccines have shown high efficacy in protecting against COVID-19, although the determinants of vaccine effectiveness and breakthrough rates are yet to be determined. We aimed at investigating several factors affecting the SARS-CoV-2 IgG Spike (S) antibody responses on admission and clinical outcomes of COVID-19 disease in fully vaccinated, hospitalized patients. Methods: 102 subjects were enrolled in the study. Blood serum samples were collected from each patient upon admission for the semiquantitative determination of the SARS-CoV-2 IgG S levels with lateral flow assays. Factors influencing vaccine responses were documented. Results: 27 subjects had a negative antibody test upon hospital admission. Out of the 102 patients admitted to the hospital, 88 were discharged and 14 died. Both the absence of anti-S SARS-CoV-2 antibodies and poor clinical outcomes of COVID-19 disease were associated with older age, lower Ct values, and a shorter period between symptom onset and hospital admission. Ct values and time between symptom onset and hospitalization were independently associated with SARS-CoV-2 IgG S responses upon admission. The PaO2/FiO2 ratio was identified as an independent predictor of in-hospital mortality. Conclusions: Host-and disease-associated factors can predict SARS-CoV-2 IgG S responses and mortality in hospitalized patients with breakthrough SARS-CoV-2 Infection. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | Journal of Personalized Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129194382&doi=10.3390%2fjpm12040640&partnerID=40&md5=827da11ff3d2eb533faf71080fcded2f | |
dc.subject | alanine aminotransferase | en |
dc.subject | aspartate aminotransferase | en |
dc.subject | astrazeneca covid19 vaccine | en |
dc.subject | C reactive protein | en |
dc.subject | corticosteroid | en |
dc.subject | covid19 vaccine biontech pfizer | en |
dc.subject | creatine kinase | en |
dc.subject | creatinine | en |
dc.subject | elasomeran | en |
dc.subject | ferritin | en |
dc.subject | lactate dehydrogenase | en |
dc.subject | probiotic agent | en |
dc.subject | SARS-CoV-2 antibody | en |
dc.subject | tozinameran | en |
dc.subject | urea | en |
dc.subject | vaxzevria | en |
dc.subject | aged | en |
dc.subject | antibody response | en |
dc.subject | Article | en |
dc.subject | body mass | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | cycle threshold value | en |
dc.subject | female | en |
dc.subject | Fisher exact test | en |
dc.subject | Horowitz index | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | Kolmogorov Smirnov test | en |
dc.subject | lateral flow immunochromatography | en |
dc.subject | logistic regression analysis | en |
dc.subject | lymphocyte count | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | platelet count | en |
dc.subject | real time reverse transcription polymerase chain reaction | en |
dc.subject | software | en |
dc.subject | MDPI | en |
dc.title | Predictors of SARS-CoV-2 IgG Spike Antibody Responses on Admission and Clinical Outcomes of COVID-19 Disease in Fully Vaccinated Inpatients: The CoVax Study | en |
dc.type | journalArticle | en |